Business
Publication of Prospectus
Publication of Prospectus.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM) OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. \n \n \n \n \n \n FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN ANY JURISDICTION.\n \n \n \n \n \n \n \n \n 13 September 2022\n \n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n \n Publication of Prospectus\n \n \n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that, further to the\n conditional share sale and purchase agreement (the \"Acquisition Agreement\") with the shareholders of Oncogeni Limited (the \"Sellers\") as announced on 22 June 2022, the Company has today received approval from the FCA of its prospectus (the \"Prospectus\") and published its Prospectus in relation to the proposed acquisition of the entire issued share capital of Oncogeni Limited (\"Oncogeni\"), the\n conditional placing for new Ordinary Shares to raise gross proceeds of £1,015,000 (the \"Placing\") and the issue of Consideration Shares (as described below).\n \n \n \n \n \n The Prospectus and an electronic copy of the Prospectus has been made available on the Company's website (https://www.roquefortplc.com/category/shareholder-documents/). The Prospectus will also be available for inspection at the National Storage Mechanism website:\n \n \n https://data.fca.org.uk/#/nsm/nationalstoragemechanism\n \n \n \n \n \n As announced on 22 June 2022 the Company entered into the Acquisition Agreement pursuant to which Roquefort Therapeutics agreed to acquire the entire issued share capital of Oncogeni for an aggregate consideration of £5,500,000\n to be satisfied by the issue of 50,000,000 new ordinary shares in the Company\n (\"Consideration Shares\") to the Se...